THERAPY OVERVIEW PTNM IN SENIOR LIVING FACILITIES

RESTORE BLADDER FUNCTION

Percutaneous tibial neuromodulation (PTNM) delivered by the NURO™ system is a safe and effective overactive bladder (OAB) treatment.1-3 It's proven to restore* bladder function without the side effects of medication.†4

How PTNM Works

The NURO system delivers electrical pulses through a needle to stimulate the afferent fibers of the tibial nerve that runs posterior to the medial malleolus and extends to the sacral nerve plexus. This treatment is called PTNM, otherwise known as percutaneous tibial neurostimulation (PTNS).

  • Evidence links OAB to dysfunctional bladder-central nervous system (CNS) communication.5
  • PTNM is thought to restore* bladder function by modulating the bladder-CNS communication pathway.
  • The therapy uses an adjustable electrical pulse to directly stimulate the peripheral tibial nerve, indirectly thought to modulate communication with the CNS to relieve symptoms of OAB, helping patients take back control.

Percutaneous Tibial Neuromodulation (PTNM) Using the NURO System

See how to deliver PTNM with the NURO system

THE NURO SYSTEM

Designed to meet the needs of senior living facilities, the NURO system delivers therapy to your OAB patients efficiently and cost-effectively. Its portability allows you to administer therapy in the comfort and privacy of the resident’s room.

THERAPY DURATION AND SEQUENCE

The resident is typically treated once per week for 30 minutes for a period of 12 weeks. No decision regarding therapy effectiveness should be made until the patient completes the 12 therapy sessions.

For residents responding to treatment, the time between therapy sessions may be slowly increased after the initial 12 therapy sessions, with the resident closely monitored for the return of symptoms. If symptoms reappear or increase in severity, the resident’s treatment schedule should revert to the last previously effective treatment schedule.


*

Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.

Most common side effects are temporary and include mild pain or skin inflammation at or near the stimulation site.


1

Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438-1443.

2

Finazzi-Agrò E, Campagna A, Sciobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva Urol Nefrol. 2005;57(2):119-123.

3

Govier FE, Litwiller S, Nitti V, et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165(4):1193-1198.

4

Peters, K. M., S. A. Macdiarmid, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182(3): 1055-1061.

5

Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491-501.